GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
(WorldNews Africa)

Issued: London UK GSK today announced encouraging results from a phase II dose-ranging study of GSK3196165 (`GSK165`), an investigational anti-granulocyte macrophage colony-stimulating factor monoclonal (anti GM-CSF) antibody, in patients with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX). These data (abstract 1938) will be presented at the 2018 American College of Rheumatology (ACR). The primary objective of this double-blind, placebo-controlled, dose-ranging study was to assess the efficacy of GSK165 in adult patients with active, moderate to severe RA. A total of 222 patients were randomised equally to receive placebo or GSK165 (37...